The burgeoning landscape of therapeutic interventions for weight disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. While both https://junaidcozk421247.governor-wiki.com/2025075/glp_3_retatrutide_a_comparative_analysis